To include your compound in the COVID-19 Resource Center, submit it here.

A2 emerges with $57M series A, engineered T cells for solid tumors

A2 debuted Tuesday with a $57 million series A round and two T cell immunotherapy strategies for solid tumors. The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech Invest.

A2

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE